Compare iShares Broad USD Investment Grade Corporate Bond (USIG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Broad USD Investment Grade Corporate Bond vs GeneDx Holdings Corp — how do they compare? iShares Broad USD Investment Grade Corporate Bond trades at $48.77 (market cap $17.53B), while GeneDx Holdings Corp trades at $67.75 (market cap $2.02B). The key difference: iShares Broad USD Investment Grade Corporate Bond is far larger — about 8.7× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Broad USD Investment Grade Corporate Bond for 44 Days and GeneDx Holdings Corp for 19 Days on average.
| USIG | WGS | |
|---|---|---|
Market Cap | $17.53B | $2.02B |
Volume | 4,695,583 | 734,640 |
Sector | Fixed Income | Health |
52-Week High | $52.69 | $167.51 |
52-Week Low | $48.54 | $34.51 |
Typical Hold Time | 44 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USIG trades at $48.73 with minimal daily movement (+0.1%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators are neutral. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake. The company maintains regular dividend distributions, with recent payments of $0.20-$0.21 per share.
The outlook remains cautious given bearish technical signals and limited fundamental data availability. Investment opportunity exists through dividend income and institutional confidence, but risks include market volatility and the need for clearer financial performance metrics to assess valuation properly.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
